Cross- and co-packaging of retroviral genomic RNAs can result in the generation of novel viral variants with unknown pathogenic potential and offer targets for anti-viral drugs and gene therapy.
Understanding the molecular mechanisms of retroviral RNA cross- and co-packaging is important for assessing the pathogenic potential of novel viral variants and developing anti-viral drugs, vaccines, and gene therapy vectors.
and are ribonucleoprotein (RNP) particles that contain a dimeric RNA genome. Retroviral particle assembly is a complex process, and how the virus is able to recognize and specifically capture the genomic RNA (gRNA) among millions of other cellular and spliced retroviral RNAs has been the subject of extensive investigation over the last two decades. The specificity towards RNA packaging requires higher order interactions of the retroviral gRNA with the structural Gag proteins. Moreover, several retroviruses have been shown to have the ability to cross-/co-package gRNA from other retroviruses, despite little sequence homology. This review will compare the determinants of gRNA encapsidation among different retroviruses, followed by an examination of our current understanding of the interaction between diverse viral genomes and heterologous proteins, leading to their cross-/co-packaging. Retroviruses are well-known serious animal and human pathogens, and such a cross-/co-packaging phenomenon could result in the generation of novel viral variants with unknown pathogenic potential. At the same time, however, an enhanced understanding of the molecular mechanisms involved in these specific interactions makes retroviruses an attractive target for anti-viral drugs, vaccines, and vectors for human gene therapy.
Ali et al. (Tue,) conducted a review in Retroviral infections. Cross- and co-packaging of retroviral genomic RNAs can result in the generation of novel viral variants with unknown pathogenic potential and offer targets for anti-viral drugs and gene therapy.